Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Not surprisingly in these trying times, our agenda is exceedingly modest. We plan to observe a day of rest by avoiding news on the telly, at least as much as possible, and otherwise reaching out to friends and family. A nap or two is also in order. And what about you? This may be a good time to assess the success of your social distancing methods and stay-at-home policy. You could also zone out with a good book. Or call someone who, unfortunately, is feeling isolated. Well, whatever you do, remember that this, too, shall pass. And stay safe.

Sanofi (SNY) chief executive Paul Hudson says the drug maker will be able to provide millions of doses of hydroxychloroquine for patients with the illness caused by the novel coronavirus if the old malaria drug proves successful in clinical trials, Reuters reports. The company is currently manufacturing at over 93% capacity during the pandemic and made a choice to “overproduce” its drugs to ensure supplies for hospitals in Europe and the U.S. facing an unprecedented crush of patients suffering from respiratory complications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.